How does deflazacort actually slow down muscle weakness in Duchenne muscular dystrophy?
Deflazacort is a corticosteroid prodrug that converts to 21-desDFZ in your body, which blocks inflammation through the glucocorticoid receptor and slows muscle fiber breakdown in DMD [3]. The exact mechanism in DMD is still being studied, but clinical trials show it delays loss of walking ability by 1–2 years [3].
Deflazacort works by turning into an active form called 21-desDFZ inside your body. This active form attaches to glucocorticoid receptors in muscle and immune cells, turning down inflammation and reducing the breakdown of muscle fibers. In DMD, this slowing of muscle damage helps boys stay mobile longer [3].
Your immune system normally attacks damaged muscle cells in DMD, making weakness worse. Deflazacort quiets this immune attack by reducing inflammatory chemicals (cytokines) and immune cell activity. Think of it like turning down the volume on a fire alarm that keeps going off inside your muscles [3].
The trade-off is that corticosteroids also suppress your whole immune system, so infections become more likely. Long-term use can weaken bones, raise blood sugar, and cause mood swings. Your doctor will monitor blood glucose, bone density, and infection signs every 3–6 months to catch problems early [3].
Ask your doctor: 'What is my target dose, and how often will we check my blood sugar and bone health?' Write down the monitoring schedule so you don't miss appointments—catching side effects early makes a big difference.